维生素D受体多态化与对Helicobacter Pylori治疗的反应之间的关联
Yousry Esam-Eldin Abo-Amer1, Amal Ahmed Mohamed2, Mohamed Mahmoud Elhoseeny3
1Mahala Hepatology Teaching Hospital, Hepatology& Gastroenterology Department, Gharbia, Elgharbia, Egypt.
Infection and drug resistance
|July 14, 2023
概括
维生素D受体 (VDR) 基因变异影响H. 杆菌的根除取得了成功. 特定的VDR多态 (rs 2228570和rs7975232) 与治疗反应相关,提供了对个性化H的洞察力. 皮洛里病毒治疗.治疗.
科学领域:
- 遗传学和分子生物学
- 胃肠病学 胃肠病学
- 药物基因组学 药物基因组学
背景情况:
- 甲状腺杆菌 (H. pylori) 是一种 甲状腺杆菌感染是一个全球性的健康问题.
- 在H.中抗处理. 杆菌感染需要了解影响治疗反应的宿主因素.
- 维生素D受体 (VDR) 基因是影响药物代谢和免疫反应的潜在候选者.
研究的目的:
- 调查维生素D受体 (VDR) 基因多态化与H.标准三重疗法的疗效之间的关联. 皮洛里病毒的根除. 根除.
- 识别特定的VDR基因变异,预测成功或失败的H. 皮洛里病毒的根除. 根除.
主要方法:
- 一个前性队列研究,涉及105人. 皮洛里阳性成年患者.
- 使用聚合酶链反应 (PCR) 的VDR基因多态的基因定型 (rs 2228570,rs7975232).
- 标准的三重根除疗法 (克拉里思罗米辛,阿莫西西林,奥梅普拉) 14天,然后进行便抗原检测H. 皮洛里病毒 确认.
主要成果:
- 标准三重治疗的整体根除率为75.2%.
- 在VDR基因多态 (ApaI和TaqI,特别是rs 2228570和rs7975232) 和治疗结果 (P <0.05) 之间观察到显著的相关性.
- 特定的基因型 (例如,rs 2228570的CT,rs7975232的AC) 与更高的根除成功有关,而其他 (例如,两者的CC) 与治疗失败有关.
结论:
- 这项研究表明,VDR基因多态 (ApaI和TaqI) 与对H.I的反应之间存在显著的关联. 脊柱炎的根除疗法. 根除疗法.
- 这些发现强调了VDR基因变异在预测H.治疗结果中的潜在作用. 杆菌感染. 感染.
- 需要对更大的队列和多样化的群体进行进一步的研究,以验证这些药物遗传学关联.
相关概念视频
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
461
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
461
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
157
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
157
01:30Peptic Ulcer Disease I: Introduction
203
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
203
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
517
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
517
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
468
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
468
01:26Peptic Ulcer Disease IV: Management
113
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
113